A Phase 3 Study to Evaluate the Efficacy and Safety of Weeky Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Cancer Receiving Radiotherapy

Grants and Contracts Details

StatusFinished
Effective start/end date4/1/05 → 3/31/12

Funding

  • AMGen: $5,524.00